Literature DB >> 16244263

Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers.

Jurgen J Fütterer1, Marc R Engelbrecht, Henkjan J Huisman, Gerrit J Jager, Christina A Hulsbergen-van De Kaa, J Alfred Witjes, Jelle O Barentsz.   

Abstract

PURPOSE: To prospectively determine the accuracy of experienced and less experienced readers in the interpretation of combined T2-weighted fast spin-echo (SE) magnetic resonance (MR) images and dynamic contrast material-enhanced MR images compared with T2-weighted fast SE alone, with respect to differentiation of stage T2 versus stage T3 prostate carcinoma, with histologic analysis serving as the reference standard.
MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained, and 124 consecutive men (age range, 42-74 years; median age, 63 years) with biopsy-proved prostate cancer underwent MR imaging and were candidates for radical prostatectomy. T2-weighted fast SE MR images and multisection dynamic contrast-enhanced MR images with a 2-second time resolution for the whole prostate were obtained. The T2-weighted and fused color-coded parametric dynamic contrast-enhanced MR images with T2-weighted images were evaluated prospectively and scored with regard to local extent by one experienced reader and evaluated retrospectively by two less experienced readers working in consensus by using a five-point scale; images with a score greater than or equal to four were considered indicative of T3 disease. Results were correlated with whole-mount section histopathologic findings, and receiver operating characteristics analysis was performed.
RESULTS: Twenty-five patients were excluded because of positive findings in the lymph nodes (n = 16), preoperative biopsy-proved seminal vesicle invasion (n = 5), and an absent dynamic dataset (n = 4). Ninety-nine patients were included in this study. The overall sensitivity, specificity, and accuracy of MR staging performance in prostate cancer with dynamic contrast-enhanced MR imaging was 69% (24 of 35 patients), 97% (62 of 64 patients), and 87% (86 of 99 patients), respectively, for the experienced reader. This difference was not significant (P = .48) when results were compared with results from the T2-weighted images. Staging performance for the less experienced readers with parametric dynamic contrast-enhanced MR imaging, however, resulted in significant improvement of the area under the receiver operating characteristics curve (A(z)) compared with T2-weighted MR imaging alone (A(z) = .66 and .82, respectively; P = .01).
CONCLUSION: The use of multisection dynamic contrast-enhanced MR imaging in staging prostate cancer showed significant improvement in staging performance for the less experienced readers but had no benefit for the experienced reader.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244263     DOI: 10.1148/radiol.2372041724

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  60 in total

1.  Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.

Authors:  B Nicolas Bloch; Elizabeth M Genega; Daniel N Costa; Ivan Pedrosa; Martin P Smith; Herbert Y Kressel; Long Ngo; Martin G Sanda; William C Dewolf; Neil M Rofsky
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

2.  The dilemma of multiorgan donors with high serum PSA--a pathologist's proposal.

Authors:  Gregor Mikuz; Rodolfo Montironi; Antonio Lopez-Beltran; Gianni Bussolati
Journal:  Virchows Arch       Date:  2006-05-05       Impact factor: 4.064

Review 3.  Is it time to consider a role for MRI before prostate biopsy?

Authors:  Hashim U Ahmed; Alex Kirkham; Manit Arya; Rowland Illing; Alex Freeman; Clare Allen; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

4.  [Importance of multiparametric MRI with respect to seminal vesicle infiltration in prostate cancer].

Authors:  M Avanesov; M Karul
Journal:  Radiologe       Date:  2013-08       Impact factor: 0.635

Review 5.  Imaging angiogenesis of genitourinary tumors.

Authors:  Ying-Kiat Zee; James P B O'Connor; Geoff J M Parker; Alan Jackson; Andrew R Clamp; M Ben Taylor; Noel W Clarke; Gordon C Jayson
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

6.  Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging.

Authors:  Fatma Nur Soylu; Yahui Peng; Yulei Jiang; Shiyang Wang; Christine Schmid-Tannwald; Ila Sethi; Scott Eggener; Tatjana Antic; Aytekin Oto
Journal:  Radiology       Date:  2013-02-25       Impact factor: 11.105

7.  The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.

Authors:  Berrend G Muller; Jurgen J Fütterer; Rajan T Gupta; Aaron Katz; Alexander Kirkham; John Kurhanewicz; Judd W Moul; Peter A Pinto; Ardeshir R Rastinehad; Cary Robertson; Jean de la Rosette; Rafael Sanchez-Salas; J Stephen Jones; Osamu Ukimura; Sadhna Verma; Hessel Wijkstra; Michael Marberger
Journal:  BJU Int       Date:  2013-11-13       Impact factor: 5.588

Review 8.  MR Imaging Biomarkers in Oncology Clinical Trials.

Authors:  Richard G Abramson; Lori R Arlinghaus; Adrienne N Dula; C Chad Quarles; Ashley M Stokes; Jared A Weis; Jennifer G Whisenant; Eduard Y Chekmenev; Igor Zhukov; Jason M Williams; Thomas E Yankeelov
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

9.  Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?

Authors:  Hye Won Lee; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

Review 10.  Multidisciplinary functional MR imaging for prostate cancer.

Authors:  Jeong Kon Kim; Yun-Jin Jang; Gyunggoo Cho
Journal:  Korean J Radiol       Date:  2009 Nov-Dec       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.